About Ionpath
Ionpath is a Healthcare company based in Menlo Park (United States) founded in 2014. Multiplexed ion beam imaging platform for tissue biopsies is developed. Ionpath has raised $18 million across 3 funding rounds from investors including Thermo Fisher Scientific, Bruker and Samsara BioCapital. The company has 37 employees. Its chief executive, as recorded, is Paul Davy. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Imaging Systems. Its legal entity is Ionpath, Inc. Its competitors include Scholar Rock, SpectraWAVE and Fluxion Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Developer of an imaging platform for tissue biopsies. It has designed a mass spec-based imaging platform for tissue biopsy called multiplexed ion beam imaging. The platform allows higher resolution and more samples can be screened simultaneously than the optical microscope and other mass spec-based imaging systems. The technology has diverse applications and can be used in research as well as diagnostic sectors.
- Headquarters Menlo Park, United States
- Employees 37
- SectorsHealthcare
- Email••••••••
- Website ionpath.com
- Social LinkedIn X
- Legal Name Ionpath, Inc.
- Total Equity Funding$18M (USD)
in 3 rounds
- InvestorsThermo Fisher Scientific
& 7 more
- Employee Count37
Funding Insights of Ionpath
Ionpath has successfully raised a total of $18M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18M
- Total Rounds 3
- Investors Count 8
All 3 funding rounds of Ionpath with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2022 | Series B | – | Thermo Fisher Scientific | – | |
| Sep 2020 | $18M | Series B | – | Samsara BioCapital | |
| Aug 2017 | Seed | – | Agile Angel | – |
8 investors in total: 8 institutional.
Investors in Ionpath
Ionpath has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Thermo Fisher Scientific, Bruker and Samsara BioCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Early-stage VC firm focused on life science startups | genoavc.com | San Francisco, United States | ||
| norwichventures.com | ||||
Early-stage venture capital investments are made in specific industry verticals. | vvp.vc | Palo Alto, United States | ||
Tech startups are invested in by this venture capital firm. | nd.capital | Woodside, United States | ||
Venture capital firm focused on multiple sectors | agileangel.com | Dallas, United States | ||
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States | |
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States |
Investor details for Ionpath
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ionpath
17 people are tracked at Ionpath (10 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Paul Davy | CEO | Leadership |
David Summa | Executive Chair | Leadership |
Frank Tucker | Vice President Of Engineering | Leadership |
Raghav Padmanabhan | Senior Director Of Data Science | Leadership |
Xinyue He | Vice President Finance | Leadership |
Harris Fienberg | Founding CEO | Leadership |
He Maria | Vice President Finance | Leadership |
Monirath Hav . | Director of Pathology & Spatial Proteomics Research | Leadership |
Jessica Finn | VP of Pathology | Leadership |
Tonin He | Vice President Finance | Leadership |
Frank Lee | Director | Board & advisors |
Mike Dybbs | Director | Board & advisors |
Paul Conley | Director | Board & advisors |
Garry Nolan | Co-Founder | Board & advisors |
Mike Angelo | Director | Board & advisors |
Sweta Bajaj | Computer Vision, Data Scientist | Team |
Sam Kimmey | Senior Scientist | Team |
Complete people profiles for Ionpath
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ionpath
3 dated milestones of Ionpath across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ionpath is founded.
- Funding First funding round.
- Funding Latest funding round, Series B,.
Competitors of Ionpath
Ionpath has 3 listed competitors in our database, 3 of them funded. They include Scholar Rock, SpectraWAVE and Fluxion Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| spectrawave.com | 2012 | Waltham, United States | $79.88M | 36 | Photonic imaging diagnostics for cardiovascular disease treatment are provided. | |
| fluxionbio.com | 2005 | San Francisco, United States | $20.85M | Microfluidics-based tools for cellular analysis are provided. |
Detailed competitors of Ionpath
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Ionpath (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ionpath
Complete news archive for Ionpath
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ionpath
Ionpath was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Ionpath is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Paul Davy is the CEO of Ionpath, as recorded in our data.
Ionpath is a funded company, having raised a total of $18M across 3 funding rounds to date.
Ionpath has 37 employees.
Developer of an imaging platform for tissue biopsies. It has designed a mass spec-based imaging platform for tissue biopsy called multiplexed ion beam imaging. The platform allows higher resolution and more samples can be screened simultaneously than the optical microscope and other mass spec-based imaging systems. The technology has diverse applications and can be used in research as well as diagnostic sectors.
Ionpath's top competitors include Scholar Rock, SpectraWAVE and Fluxion Biosciences.
Ionpath has 8 investors. Key investors include Thermo Fisher Scientific, Bruker, Samsara BioCapital, Genoa Ventures, and Norwich Ventures.
Ionpath operates through Ionpath, Inc..